Veradermics Announces Encouraging Phase 2 Results for VDPHL01 in Female Pattern Hair Loss with Over 22 Hairs/cm² Average Growth

Overview of Veradermics and VDPHL01

Veradermics, Incorporated is a Delaware-based specialty dermatology company located at 470 James Street, New Haven, Connecticut. Classified as an emerging growth company, it has a limited operating history and currently markets no approved products. The company’s core focus is the development and potential commercialization of VDPHL01, an extended-release oral minoxidil formulation targeting pattern hair loss in both men and women.

VDPHL01 is characterized as a proprietary formulation distinct from existing immediate-release oral minoxidil products on the market. Veradermics identifies VDPHL01 as its lead candidate, with the company’s future success heavily reliant on its regulatory approval and commercialization. The company anticipates ongoing substantial losses and will require additional funding to meet its development and commercial goals.

Design and Structure of Study '207'

Study '207' is a multicenter, open-label Phase 2 clinical trial enrolling 49 participants: 21 adult males and 28 adult females with pattern hair loss. The primary goal was to establish proof of concept regarding safety and efficacy after twelve months of VDPHL01 treatment across both genders.

Male participants received 8.5 mg of VDPHL01 twice daily, while female participants were assigned to either 4.5 mg once daily or 4.5 mg twice daily dosing regimens. The open-label nature meant both participants and investigators knew the treatment administered. The topline data released on July 15, 2026, focuses specifically on female participant outcomes at six months.

Hair Count Improvements in Female Participants at Six Months

Veradermics reported statistically significant increases in non-vellus Target Area Hair Count among female participants at Month 6. Those receiving once daily dosing experienced an average hair count increase of 22.7 hairs/cm8, while the twice daily group saw an average increase of 23.3 hairs/cm8. The company emphasized consistent responses across participants, indicating a reliable treatment effect rather than isolated high responders.

The data suggest VDPHL01 may offer a differentiated clinical profile characterized by rapid onset and consistent efficacy across the female cohort. These interim results were measured at six months within a study designed for a full twelve-month treatment period. Full twelve-month data were not included in this announcement.

Patient-Reported Outcomes Using the AAIRS Scale

Study '207' also utilized the Androgenetic Alopecia Impact Rating Scale (AAIRS) to capture participant perceptions of hair coverage changes. At Month 6, 88.9% of women on once daily dosing and 90.0% on twice daily dosing rated their hair coverage as 'improved' or 'much improved.'

Veradermics highlighted this strong alignment between objective hair count gains and patient-reported improvements as evidence of clinical meaningfulness. Such patient-reported outcomes are increasingly valued by regulatory agencies in dermatology clinical trials.

Investigator Assessments Confirm Hair Coverage Improvements

Independent clinical investigators also assessed hair coverage improvements using the same 'improved' or 'much improved' criteria. They rated 100% of female participants in the once daily group and 90% in the twice daily group as showing improvement at Month 6.

This concordance between patient and investigator assessments reinforces the robustness of the trial results. The perfect investigator-rated improvement in the once daily arm underscores strong agreement with the objective hair count data.

Early Hair Growth Noted at Two Months

Veradermics noted hair growth onset as early as Month 2, the earliest time point measured in Study '207.' At this stage, 67.2% of female participants were assessed by investigators as improved, with 63.2% self-reporting improvement in hair coverage.

This early response is part of VDPHL01’s potentially differentiated profile, addressing a common limitation of existing hair loss treatments related to delayed onset. The company did not provide direct comparisons to other therapies, and this characterization reflects its own evaluation rather than head-to-head data.

Safety and Tolerability in Female Participants

VDPHL01 was generally well tolerated over six months among female participants, with no serious treatment-related adverse events or cardiac-origin adverse events of special interest reported. This is notable given systemic minoxidil’s historical association with cardiovascular side effects, which have influenced dosing approaches.

The most common adverse events were hypertrichosis (unwanted hair growth outside the scalp) and peripheral edema (swelling of extremities), consistent with minoxidil’s known profile. The absence of serious cardiac events at studied doses is an encouraging safety signal, though the open-label design and early phase status limit definitive conclusions.

Press Release and Investor Presentation Details

Veradermics filed two exhibits alongside the July 15, 2026 disclosure: Exhibit 99.1, the company’s press release, and Exhibit 99.2, the investor presentation from its conference call and webcast. Both are incorporated by reference and publicly accessible.

The company clarified these Regulation FD Disclosure materials are not considered "filed" under Section 18 of the Securities Exchange Act of 1934, thus exempt from related liabilities. This standard practice does not affect investor access. The disclosure was signed by Reid Waldman, M.D., CEO of Veradermics.

Risk Factors Highlighted by Veradermics

Veradermics included extensive forward-looking statements outlining risks such as limited operating history, absence of approved products, ongoing substantial losses, and the need for additional funding. The company also identified potential risks from adverse events during clinical evaluation, competitive pressures in the hair loss market, and uncertainty regarding regulatory approval timelines or outcomes.

The company emphasized its reliance on VDPHL01’s successful approval and commercialization for future success, warning that failure to achieve this would significantly harm its business. These disclosures align with risks detailed in its 2025 Annual Report on Form 10-K.

Positioning of VDPHL01 in the Hair Loss Treatment Market

Androgenetic alopecia, or pattern hair loss, affects many adults and has limited approved treatment options. Oral minoxidil is gaining attention for treating male and female pattern hair loss, with extended-release formulations like VDPHL01 aiming to optimize drug delivery for better efficacy and tolerability compared to immediate-release products.

Veradermics positions VDPHL01 as a proprietary extended-release oral minoxidil with potential clinical advantages. The Phase 2 Study '207' data represent the company’s most advanced public clinical evidence to date. No direct comparisons to existing minoxidil products or investigational agents were disclosed. The company cautions that data interpretation carries uncertainties typical of clinical-stage development. VDPHL01 has yet to complete Phase 3 trials or obtain regulatory approval from the FDA or other agencies.